Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Celonic AG. (5/8/18). "Press Release: Celonic AG Appoints Soenke Brunswieck as Vice President Cell & Gene Therapy". Basel.

Organisations Organisation Celonic AG
  Group Promethera (Group)
  Organisation 2 PharmaCell B.V.
  Group Lonza (Group)
Products Product contract manufacturing (biologicals)
  Product 2 drug development services
  Index term 2 PharmaCell–Lonza: investment, 201704 acquisition of PharmaCell BV by Lonza
Persons Person Brunswiek, Soenke (PharmCell 201501 Director Business Development)
  Person 2 Matentzoglu, Konstantin (Celonic 201711 CEO before Trenzyme GmbH 201202 Managing Director)

Celonic AG, the Swiss biologics contract development and manufacturing organization, has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new portfolio of CDMO Services in Cell & Gene Therapy domain.

“Cell & Gene Therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)”, said Dr. Konstantin Matentzoglu, CEO at Celonic AG. "Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of Cell & Gene Therapy Products", added Dr. Matentzoglu.

Soenke is on-boarded by Celonic based on his excellent track record as Director of Business Development and Project Management at PharmaCell BV (now Lonza Netherlands BV), one of the leading CDMOs for Cell & Gene Therapies, based in the Netherlands. Prior to PharmaCell, Soenke was the Director of Marketing & Sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in Cell and Gene Therapy.

Soenke Brunswieck, VP of Cell & Gene Therapy at Celonic added: „Celonic, as a premium quality-driven bio-pharmaceutical CDMO, now entering into the Cell & Gene Therapy services space, is taking a key strategic step to continue adding value to the fast-growing industry by developing and commercializing Cell Therapy & Gene Therapy Products“.

About Celonic

Celonic AG is a privately owned CDMO based in Basel, Switzerland, providing comprehensive process development and manufacturing services for New Biological Entities (NBEs), Biosimilars, and Cell Therapy & Gene associated services worldwide.

Celonic’s services include the development of cell lines, production processes, as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances and drug product. In addition, Celonic licenses its CHOvolution™ and GEX™ cell line technologies to clients, drug developers and service providers. The service portfolio is now extended to the manufacturing of gene vectors and allogenic cell batches. Applying empathy, efficiency and excellence, Celonic goes one step beyond expectations in all business aspects in order to help its clients attain their goals more efficiently and reliably.

About Soenke Brunswieck, Vice President Cell & Gene Therapy

Prior to joining Celonic, Soenke was working as Director Business Development & Project Management at PharmaCell BV (now Lonza Netherlands BV), one of the leading CMOs in Cell & Gene Therapy. From 2002 to 2013, he was working for CellGenix (Freiburg, Germany) as Director Marketing & Sales, where he was responsible the creation and successful growth of the market for GMP-reagents as used in cell therapy on a global basis. He also was working in several Marketing & Sales positions at Pharmacia & Upjohn, Glaxo Welcome and SmithKlineBeecham. Soenke studied Biology at the Technical University Munich and Max Planck Institute of Psychiatry. He obtained his PhD at the Klinikum Rechts der Isar in Munich.


Lysiane Dietsch
Marketing Director
Celonic AG
Eulerstrasse 55
4051 Basel
+41-61-564 91 50

Soenke Brunswieck
Vice President Cell & Gene Therapy
Celonic AG
Eulerstrasse 55
4051 Basel

Record changed: 2018-05-09


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Promethera (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top